0.840
-0.14 (-14.29%)
| Previous Close | 0.980 |
| Open | 1.00 |
| Volume | 1,340,113 |
| Avg. Volume (3M) | 111,844 |
| Market Cap | 11,947,740 |
| Price / Earnings (Forward) | 2.97 |
| Price / Sales | 6.79 |
| Price / Book | 1.69 |
| 52 Weeks Range | |
| Earnings Date | 28 Aug 2025 - 1 Sep 2025 |
| Operating Margin (TTM) | -1,127.37% |
| Quarterly Revenue Growth (YOY) | 15.50% |
| Total Debt/Equity (MRQ) | 1.91% |
| Current Ratio (MRQ) | 4.38 |
| Operating Cash Flow (TTM) | -7.64 M |
| Levered Free Cash Flow (TTM) | -4.82 M |
| Return on Assets (TTM) | -53.18% |
| Return on Equity (TTM) | -134.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Can-Fite Biopharma Ltd Sponsore | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
|
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Institutions | 1.16% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kohmann Bosshard Financial Services, Llc | 31 Dec 2024 | 3,401 |
| Avion Wealth | 31 Dec 2024 | 0 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Can-Fite Reports H1 2025 Financial Results and Clinical Update |
| 30 Jul 2025 | Announcement | Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone |
| 28 Jul 2025 | Announcement | Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia |
| 28 Jul 2025 | Announcement | Can-Fite Announces Up To $15.0 Million Public Offering |
| 16 Jun 2025 | Announcement | Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 12 Nov 2013 | - | 25 Nov 2013 | 0.169622 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2013 | 0.170 | 1 | 0.02 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |